PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. - Wikidata - wikimedia - TriplyDB

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.

http://www.wikidata.org/entity/Q37686796

about

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status Strategies to Inhibit Myc and Their Clinical Applicability Therapeutic Approaches Targeting MYC-Driven Prostate Cancer In vivo Reprogramming of Cancer Metabolism by MYC.A functional SUMO-motif in the active site of PIM1 promotes its degradation via RNF4, and stimulates protein kinase activity.PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.MYC-Master Regulator of the Cancer Epigenome and Transcriptome.MYC Modulation around the CDK2/p27/SKP2 Axis PIM1: a promising target in patients with triple-negative breast cancer.Novel cooperative pathway of c-Myc and Furin, a pro-protein convertase, in cell proliferation as a therapeutic target in ovarian cancers.PIM2 interacts with tristetraprolin and promotes breast cancer tumorigenesis.Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures.Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.Pim1 supports human colorectal cancer growth during glucose deprivation by enhancing the Warburg effect.Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer.Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.Applications of RNA Indexes for Precision Oncology in Breast Cancer PIM Kinase as an Executional Target in Cancer In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer Downregulation of PIM1 regulates glycolysis and suppresses tumor progression in gallbladder cancer

P2860

Q33591876-13D98479-DC84-41C7-BDFF-21469C9C4B39 Q36278557-C92158FC-E411-4535-ABD1-679F31735C53 Q36303678-B980F131-678F-424F-959F-C499F94198AF Q37676253-E6575588-8D9D-45D0-8041-7BD9653954E4 Q37746816-E39EAC38-DB72-4F73-9677-E59C360D342D Q38723222-97CB5089-2BB5-4DFC-B001-B2E1E1805BBA Q38735131-624C5982-9126-455B-A802-F74BCBADBA8D Q39306981-4E058E74-D28B-4BFA-B825-DDF23DD75BDE Q39406924-307F15D4-3F0D-4D05-9FDB-F1EC87B0BA2D Q39443294-C1B4BEB4-4440-4131-957A-CC48963A15B4 Q49386354-F5A72145-8DB0-44E8-A2DB-182425C6BBD8 Q52344482-F69DA6C8-9FED-4CD3-97CA-E76E87A9952D Q52348476-8F87B3A1-C7B2-4DFC-8970-B37B6D5E3BF4 Q54978916-13163FB0-1DFB-43CC-886A-6B195C2FD9A5 Q54982371-BF682504-D9FF-4BBE-8624-BA1C1725F739 Q55012051-99092526-7512-4933-A78A-32C467FCD0EA Q55496770-6F36B290-D71E-4B05-A147-C014DA639DC8 Q57113927-56B93B31-CCC8-4087-9251-C7076C5C3305 Q58128483-E5CE4280-1031-4911-BBE8-528678BC08D0 Q58695321-F2B4C23A-D75B-4014-AC49-DA8A861F0C43 Q59126036-F0EDFC49-C70D-4571-8569-22ECAF3D2D73

P2860

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.

http://www.wikidata.org/entity/Q37686796

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PIM1 kinase inhibition as a ta ...... with elevated MYC expression.

@en

PIM1 kinase inhibition as a ta ...... with elevated MYC expression.

@nl

type

label

PIM1 kinase inhibition as a ta ...... with elevated MYC expression.

@en

PIM1 kinase inhibition as a ta ...... with elevated MYC expression.

@nl

prefLabel

PIM1 kinase inhibition as a ta ...... with elevated MYC expression.

@en

PIM1 kinase inhibition as a ta ...... with elevated MYC expression.

@nl

P1433

Q37686796-AF4736B6-FCAA-4772-B921-BAA5B828E206

P1476

Q37686796-20793DF0-DDFB-431B-B2C4-2FF70C298983

P2093

Q37686796-048F67B8-138A-4EE2-B042-7B2FD6DB7179

Q37686796-276B90DB-4514-4784-A52A-324EBDC735B4

Q37686796-3790280F-0440-42AB-8137-C6F9C292F696

Q37686796-5EB19F0D-E632-49A6-8FDD-AE9081912B67

Q37686796-6531FE5C-8489-4128-A3B1-552587FEA519

Q37686796-6CB48A92-EE5B-4E88-8291-4B94633D811A

Q37686796-7985FE76-A8EE-4134-BF11-D0070BF9C193

Q37686796-7D6EB4CD-962E-45C3-9370-8B3570553065

Q37686796-8916B0EA-0D1B-4C8D-8770-302A2666D4CA

Q37686796-931A4E0F-5E17-4907-BAD5-3D2A830FCA75

P2860

Q37686796-04D38016-EF02-4FAE-9D44-EC85EA3FD17C

Q37686796-0897B432-CCF6-46FC-8264-C81549E15AEF

Q37686796-08997809-D350-4E26-9068-4BAD6F9C95E2

Q37686796-09036B38-67B0-44BE-9434-73B9F60655FC

Q37686796-0E44DC4D-3D9A-4DD0-B1A0-32C97E8D7E70

Q37686796-0E902007-4FFC-426C-A1B3-F431E5EEAE34

Q37686796-1620C673-94A8-48E2-8FE8-C4468DD4A8F8

Q37686796-1883DE9F-D792-4AE4-B0C4-7E9F884F6BCF

Q37686796-22640300-D22D-49BE-9295-EA328C699F8A

Q37686796-261AE497-FE37-4A2E-BD44-10399819F17E

P2888

Q37686796-A5268B2A-B16C-4F70-BBD0-7CDAF54B7040

P304

Q37686796-4C2EDB2D-1854-4EE6-B7EC-C8A906B81E2D

P31

Q37686796-B9FFA27A-EC63-492E-BD39-D6B343D88413

P356

Q37686796-1C79BDEE-0755-4B77-A4F0-86C323B7CE74

P407

Q37686796-21190706-DE4B-4A4E-AB02-DF40C887FD49

P433

Q37686796-9FD871EB-CCCB-4CA6-99BB-06B0776FAEC7

P478

Q37686796-A59B3A37-BC1F-4149-83A9-236CD0A8D59F

P50

Q37686796-2F214875-AFD8-48F0-8B9C-3A9B2EC8F723

Q37686796-F91C97ED-62B0-4D64-9FAD-148DEC224F66

P577

Q37686796-E75026F2-8DE4-4EDF-B05D-8FB36A52DC7F

P698

Q37686796-16F2B261-E0E8-4C70-A270-7930FA0AAA0C

P932

Q37686796-F3600E15-5E10-490C-8271-AFEA115FD595

P356

P1433

Nature Medicine

P1476

PIM1 kinase inhibition as a ta ...... with elevated MYC expression.

@en

P2093

Alexandra N Corella

http://www.w3.org/2001/XMLSchema#string

Alexey V Bazarov

http://www.w3.org/2001/XMLSchema#string

Alicia Y Zhou

http://www.w3.org/2001/XMLSchema#string

Andrei Goga

http://www.w3.org/2001/XMLSchema#string

Brittany N Anderton

http://www.w3.org/2001/XMLSchema#string

Christina Yau

http://www.w3.org/2001/XMLSchema#string

Dai Horiuchi

http://www.w3.org/2001/XMLSchema#string

Devon A Lawson

http://www.w3.org/2001/XMLSchema#string

Henok Eyob

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

P2860

WGCNA: an R package for weighted correlation network analysis

Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels

The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs

Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors

Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

Comprehensive molecular portraits of human breast tumours

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinica

c-Myc-regulated microRNAs modulate E2F1 expression

P2888

P304

1321-1329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.4213

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Michael McManus

P577

2016-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27775705

http://www.w3.org/2001/XMLSchema#string

P932

5341692

http://www.w3.org/2001/XMLSchema#string